Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sun Fights US Charges Over Delays

Indian Firm Pushes Back Against Charges Of Delaying Market Entry

Executive Summary

Sun Pharmaceutical Industries is back before US courts as it contests US antitrust charges filed by plaintiffs over the delayed market entry of generic versions of three major drugs.

You may also be interested in...



Sun Pharma Challenges US Antitrust Ruling

India’s Sun Pharma has sought leave to appeal a US court ruling rejecting the company’s bid for dismissal of a multidistrict antitrust lawsuit involving its troubled Ranbaxy subsidiary.

Ex-Sun Employee Alleges Reprisal For Opposing US Off-Label Practices

A Sun Pharma executive dismissed earlier this year has claimed retaliation by the company after she objected to the Indian firm’s alleged off-label marketing practices. Sun refutes the allegations and vows to vigorously defend itself, while experts suggest a settlement may be the way forward.

Sun's China, Japan Plans Gather Pace

Sun expects interleukin-23-targeting drugs to stay a preferred treatment option for psoriasis in the US and saw some sales uptick for its Ilumya in that market in Q2, although it isn’t keen on an auto injector option. Management was also upbeat on prospects in China and Japan.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB149423

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel